Non-small Cell Lung Cancer Therapeutics Market To Reach $63.5 Billion By 2033

Non-small Cell Lung Cancer Therapeutics Market Growth & Trends

The global non-small cell lung cancer therapeutics market size is expected to reach USD 63.5 billion by 2033, registering a CAGR of 12.9% from 2026 to 2033, according to a new report by Grand View Research, Inc. The non-small cell cancer therapeutics (NSCLC) market is anticipated to witness significant growth during the forecast period. This can be attributed to the high investment by market players in the research and development of lung cancer therapy, presence of a rich pipeline, and increasing penetration of drugs during the forecast period.

Introduction of several drugs in various geographical regions is likely to drive the market during the forecast period. For instance, in October 2016, the FDA granted Breakthrough Therapy Designation to Alecensa (alectinib), a drug developed by Genentech to treat ALK-positive NSCLC as a first-line treatment. The drug has been approved in the U.S., Japan, Canada, Hong Kong, South Korea, Kuwait, and Israel.

Presence of a strong pipeline of drugs for non-small cell lung cancer helps propel the market during the forecast period. Bristol-Myers Squibb Company, Orion Corporation, Merck KGaA, AstraZeneca, F. Hoffmann-La Roche Ltd, and Pfizer, Inc. have major molecules in the pipeline.

 Request a free sample copy or view report summary: Non-small Cell Lung Cancer Therapeutics Market Report

Non-small Cell Lung Cancer Therapeutics Market Report Highlights

• By type, the adenocarcinoma segment held the highest market share of 43.5% in 2025.The Squamous Cell Carcinoma (SCC) segment is projected to register the fastest CAGR of 13.5% over the forecast period.

• By treatment, the targeted therapy segment held the highest market share of 50.8% in 2025.The chemotherapy segment is expected to witness significant growth, registering a CAGR of 13.8% over the forecast period.

• By distribution channel, the hospital pharmacy segment held the highest market share of 67.1% in 2025.The drug store and retail pharmacy segment is expected to witness significant growth, registering a CAGR of 12.3% over the forecast period.

• The North America non-small cell lung cancer therapeutics market dominated with a share of 35.4% in 2025. The non-small cell lung cancer therapeutics market in the U.S. accounted for the largest share of North America.

• The non-small cell lung cancer therapeutics market in Asia Pacific is projected to register the fastest CAGR of 13.9% during the forecast period.

Non-small Cell Lung Cancer Therapeutics Market Segmentation

Grand View Research has segmented global non-small cell lung cancer therapeutics market report based on type, treatment, distribution channel, and region:

Non-small Cell Lung Cancer Therapeutics Type Outlook (Revenue, USD Billion, 2021 - 2033)

• Squamous Cell Carcinoma

• Large Cell Carcinoma

• Adenocarcinoma

• Others

Non-small Cell Lung Cancer Therapeutics Treatment Outlook (Revenue, USD Billion, 2021 - 2033)

• Chemotherapy

• Targeted Therapy

• Immunotherapy

• Others

Non-small Cell Lung Cancer Therapeutics Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)

• Hospital Pharmacy

• Drug Store and Retail Pharmacy

• Online Pharmacy

Non-small Cell Lung Cancer Therapeutics Regional Outlook (Revenue, USD Billion, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Non-small Cell Lung Cancer Therapeutics Market

• AstraZeneca PLC

• Merck & Co., Inc.

• F. Hoffmann-La Roche Ltd.

• Bristol Myers Squibb

• Johnson & Johnson

• Pfizer Inc.

• Novartis AG

• Eli Lilly and Company

• GSK plc

• Boehringer Ingelheim